Levocarnitine Oral Solution Receives Drug Registration Certificate
July 31, 2026
Source: drugdu
47
Nanfang Finance News, July 28th - Progen PharmaceuticalsThe company announced that its controlling subsidiary, Zhejiang Procon Pharmaceutical Co., Ltd., received a Drug Registration Certificate for Levocarnitine Oral Solution issued by the National Medical Products Administration. This product is used to treat primary systemic carnitine deficiency, and also for the short-term and long-term treatment of secondary carnitine deficiency caused by congenital metabolic abnormalities.
https://finance.eastmoney.com/a/202607283823563474.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- While Da Vinci Remains in “Remote Control” Mode, Cornerstone Robotics Has Evolved to “Autonomous Operation”—A Technological Leap for Domestic Surgical Robots July 31, 2026
- Carbamazepine Extended-Release Tablets (II) Receive Drug Registration Certificate July 31, 2026
- Application for drug registration and marketing authorization of dapagliflozin tablets accepted July 31, 2026
- China Biopharmaceutical and Indonesia’s Tempo Scan establish a joint venture with China Biopharmaceutical holding a 51% stake to expand the Southeast Asian pharmaceutical market July 31, 2026
- Subsidiary’s application for clinical trial registration of GenSci144 tablets for domestic production approved July 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
